Web4. máj 2024 · In patients with refractory or relapsed PMBCL, stem cell transplant significantly improved overall survival. PMBCL had distinct gene expression signatures compared with overall DLBCL–NOS but... WebPatients with either no response to immunochemotherapy or relapse within 12 months after stem-cell transplantation had inferior survival with a median OS of 5.9 months (95% CI = …
Management of relapsed/refractory DLBCL - PubMed
WebAfter a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively ( P <0.001). WebWe evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined … o\\u0027chiese nation
Relapsed or refractory classical Hodgkin lymphoma: which …
Web5. nov 2024 · Introduction:Patients with indolent non-Hodgkin lymphomas (iNHL), including follicular lymphoma (FL), have high response to first-line treatment. However, retreatment … Web10. sep 2024 · Some data show that across all therapies, the 4-year rate of overall survival after relapse is 28%, but significantly improves to 51% for patients who undergo ASCT. 9 A systematic review of observational and interventional studies reported a median survival of 10 months after relapse, in patient populations that include a mix of those who … Web9. okt 2024 · While survival rates of patients receiving consolidative RT peri-ASCT due to residual disease were similar at 24 months, these patients had inferior five-year survival rates (PFS: 53.0%, OS... We would like to show you a description here but the site won’t allow us. イケメンですね 沖縄 ホテル